Atossa Therapeutics Inc
NASDAQ:ATOS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Atossa Therapeutics Inc
NASDAQ:ATOS
|
US |
|
Mersen SA
F:CBE
|
FR |
|
S
|
Sumitomo Metal Mining Co Ltd
DUS:S19
|
JP |
|
Parrot SA
F:P2W
|
FR |
|
Pointerra Ltd
OTC:PTRRF
|
AU |
|
Universal Music Group NV
F:0VD
|
NL |
|
G
|
Gibraltar Industries Inc
XMUN:GI2
|
US |
|
P
|
PPL Corp
DUS:PP9
|
US |
Intrinsic Value
Is ATOS undervalued or overvalued?
See the intrinsic value estimate for
Atossa Therapeutics Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Atossa Therapeutics Does
Atossa Therapeutics is a clinical-stage drug developer focused on breast cancer and other breast health conditions. The company works on treatments meant to be taken by patients, with a pipeline centered on medicines that can reduce cancer risk, treat early disease, or help in combination with other therapies. It does not sell consumer products; its business is built around advancing drug candidates through research and clinical testing.
- Headquarters
- United States of America US
- Employees
- 16
- IPO date
- Nov 8, 2012
Revenue & Expenses Breakdown
Atossa Therapeutics Inc
Earnings Waterfall
Atossa Therapeutics Inc
The intrinsic value for
Atossa Therapeutics Inc (ATOS) under the Base Case is hidden USD.
Compared with the current market price of 2.37 USD, the stock appears hidden.